Life Sciences M&A Activity Signals Strategic Shift Toward Larger, High-Stakes Deals

Share!

Risk & Insurance - Jan 29, 2026

Despite declining transaction volume in 2024, life sciences companies are pursuing bigger acquisitions to secure drug portfolios, integrate AI capabilities, and navigate the looming patent cliff. The post Life Sciences M&A Activity Signals Strategic Shift Toward Larger, High-Stakes Deals appea...

Read Full Article

Recommended Articles

Slow Hiring Amid Resilient GDP Creates Mixed Signals for Workers’ Compensation in 2026

Posted: Mar 30, 2026

The U.S. economy grew at a 2.0% pace in 2025, but the labor market experienced its weakest job growt...

Read Article

AI Tops Insurance Executive Priorities as Regulatory Concerns and Market Volatility Reshape the Risk Landscape

Posted: Mar 30, 2026

AI has become the top priority for insurance industry leaders heading into 2026, according to the In...

Read Article

The AI Confidence Gap: Why Workers’ Compensation Leaders Need Better Governance Before Deployment

Posted: Mar 29, 2026

Misunderstanding artificial intelligence (AI) could put organizations and patients at risk. Here's w...

Read Article